Literature DB >> 31903227

Impact of clinical features of epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) patients on osimertinib efficacy.

Chiara Lazzari1, Vanesa Gregorc1, Mariacarmela Santarpia2.   

Abstract

Entities:  

Year:  2019        PMID： 31903227      PMCID： PMC6940227          DOI： 10.21037/jtd.2019.10.67

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  24 in total

1.  Large-scale screening for somatic mutations in lung cancer.

Authors:  Rafael Rosell; Niki Karachaliou
Journal:  Lancet       Date:  2016-01-15       Impact factor: 79.321

2.  Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.

Authors:  Mark G Kris; Bruce E Johnson; Lynne D Berry; David J Kwiatkowski; A John Iafrate; Ignacio I Wistuba; Marileila Varella-Garcia; Wilbur A Franklin; Samuel L Aronson; Pei-Fang Su; Yu Shyr; D Ross Camidge; Lecia V Sequist; Bonnie S Glisson; Fadlo R Khuri; Edward B Garon; William Pao; Charles Rudin; Joan Schiller; Eric B Haura; Mark Socinski; Keisuke Shirai; Heidi Chen; Giuseppe Giaccone; Marc Ladanyi; Kelly Kugler; John D Minna; Paul A Bunn
Journal:  JAMA       Date:  2014-05-21       Impact factor: 56.272

3.  Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance.

Authors:  Helena A Yu; Ken Suzawa; Emmet Jordan; Ahmet Zehir; Ai Ni; Ryan Kim; Mark G Kris; Matthew D Hellmann; Bob T Li; Romel Somwar; David B Solit; Michael F Berger; Maria Arcila; Gregory J Riely; Marc Ladanyi
Journal:  Clin Cancer Res       Date:  2018-03-12       Impact factor: 12.531

Review 4.  Global Cancer Incidence and Mortality Rates and Trends--An Update.

Authors:  Lindsey A Torre; Rebecca L Siegel; Elizabeth M Ward; Ahmedin Jemal
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-12-14       Impact factor: 4.254

5.  CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3).

Authors:  Yi-Long Wu; Myung-Ju Ahn; Marina Chiara Garassino; Ji-Youn Han; Nobuyuki Katakami; Hye Ryun Kim; Rachel Hodge; Paramjit Kaur; Andrew P Brown; Dana Ghiorghiu; Vassiliki A Papadimitrakopoulou; Tony S K Mok
Journal:  J Clin Oncol       Date:  2018-07-30       Impact factor: 44.544

6.  Osimertinib in patients with T790M mutation-positive, advanced non-small cell lung cancer: Long-term follow-up from a pooled analysis of 2 phase 2 studies.

Authors:  Myung-Ju Ahn; Chun-Ming Tsai; Frances A Shepherd; Lyudmila Bazhenova; Lecia V Sequist; Toyoaki Hida; James C H Yang; Suresh S Ramalingam; Tetsuya Mitsudomi; Pasi A Jänne; Helen Mann; Mireille Cantarini; Glenwood Goss
Journal:  Cancer       Date:  2018-12-04       Impact factor: 6.860

7.  Impact of clinical features on the efficacy of osimertinib therapy in patients with T790M-positive non-small cell lung cancer and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors.

Authors:  Yasuhiro Kato; Yukio Hosomi; Kageaki Watanabe; Makiko Yomota; Shoko Kawai; Yusuke Okuma; Kaoru Kubota; Masahiro Seike; Akihiko Gemma; Tatsuru Okamura
Journal:  J Thorac Dis       Date:  2019-06       Impact factor: 2.895

8.  Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.

Authors:  Tony S Mok; Yi-Long Wu; Myung-Ju Ahn; Marina C Garassino; Hye R Kim; Suresh S Ramalingam; Frances A Shepherd; Yong He; Hiroaki Akamatsu; Willemijn S M E Theelen; Chee K Lee; Martin Sebastian; Alison Templeton; Helen Mann; Marcelo Marotti; Serban Ghiorghiu; Vassiliki A Papadimitrakopoulou
Journal:  N Engl J Med       Date:  2016-12-06       Impact factor: 91.245

9.  Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors.

Authors:  Sandra Ortiz-Cuaran; Matthias Scheffler; Dennis Plenker; Llona Dahmen; Andreas H Scheel; Lynnette Fernandez-Cuesta; Lydia Meder; Christine M Lovly; Thorsten Persigehl; Sabine Merkelbach-Bruse; Marc Bos; Sebastian Michels; Rieke Fischer; Kerstin Albus; Katharina König; Hans-Ulrich Schildhaus; Jana Fassunke; Michaela A Ihle; Helen Pasternack; Carina Heydt; Christian Becker; Janine Altmüller; Hongbin Ji; Christian Müller; Alexandra Florin; Johannes M Heuckmann; Peter Nuernberg; Sascha Ansén; Lukas C Heukamp; Johannes Berg; William Pao; Martin Peifer; Reinhard Buettner; Jürgen Wolf; Roman K Thomas; Martin L Sos
Journal:  Clin Cancer Res       Date:  2016-06-01       Impact factor: 12.531

10.  AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.

Authors:  Darren A E Cross; Susan E Ashton; Serban Ghiorghiu; Cath Eberlein; Caroline A Nebhan; Paula J Spitzler; Jonathon P Orme; M Raymond V Finlay; Richard A Ward; Martine J Mellor; Gareth Hughes; Amar Rahi; Vivien N Jacobs; Monica Red Brewer; Eiki Ichihara; Jing Sun; Hailing Jin; Peter Ballard; Katherine Al-Kadhimi; Rachel Rowlinson; Teresa Klinowska; Graham H P Richmond; Mireille Cantarini; Dong-Wan Kim; Malcolm R Ranson; William Pao
Journal:  Cancer Discov       Date:  2014-06-03       Impact factor: 39.397
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.